A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Public ClinicalTrials.gov record NCT05002569. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
Study identification
- NCT ID
- NCT05002569
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,093 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Nivolumab + Relatlimab Fixed Dose Combination Biological
Biological
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2021 (Actual)
- Primary completion
- Dec 16, 2024 (Actual)
- Completion
- Apr 2, 2025 (Actual)
- Last update posted
- Jan 8, 2026
2021 – 2025
United States locations
- U.S. sites
- 43
- U.S. states
- 23
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0176 | Birmingham | Alabama | 35249 | — |
| Local Institution - 0164 | Springdale | Arkansas | 72762 | — |
| Local Institution - 0200 | Los Angeles | California | 90025 | — |
| Local Institution - 0185 | Palo Alto | California | 94304 | — |
| Local Institution - 0162 | San Francisco | California | 94115 | — |
| Saint John's Cancer Institute | Santa Monica | California | 90404 | — |
| Local Institution - 0138 | Aurora | Colorado | 80045 | — |
| Local Institution - 0166 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0243 | Miami | Florida | 33136 | — |
| Washington University School Of Medicine | Miami | Florida | 33136 | — |
| Local Institution - 0179 | Pensacola | Florida | 32504 | — |
| Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center | Tampa | Florida | 33612 | — |
| Local Institution - 0191 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0148 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0202 | Chicago | Illinois | 60611 | — |
| Local Institution - 0177 | Peoria | Illinois | 61615 | — |
| Local Institution - 0223 | Fort Wayne | Indiana | 46804 | — |
| University of Iowa-Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| Local Institution - 0178 | Westwood | Kansas | 66205 | — |
| Dana-Farber Cancer Institute-Melanoma | Boston | Massachusetts | 02215 | — |
| Local Institution - 0258 | Ann Arbor | Michigan | 48109 | — |
| Local Institution | Grand Rapids | Michigan | 49503 | — |
| Local Institution - 0133 | Minneapolis | Minnesota | 55407 | — |
| Local Institution - 0139 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0206 | Morristown | New Jersey | 07960 | — |
| Local Institution - 0140 | New York | New York | 10016 | — |
| Icahn School Of Medicine At Mount Sinai | New York | New York | 10029 | — |
| Local Institution - 0210 | New York | New York | 10065 | — |
| Local Institution - 0130 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0145 | Durham | North Carolina | 27710 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| Local Institution - 0141 | Cleveland | Ohio | 44195 | — |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C | Columbus | Ohio | 43210 | — |
| Local Institution - 0267 | Allentown | Pennsylvania | 18103 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Local Institution - 0125 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0171 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0147 | Germantown | Tennessee | 38138 | — |
| Local Institution - 0183 | Nashville | Tennessee | 37232 | — |
| Local Institution - 0146 | Austin | Texas | 78731 | — |
| Local Institution - 0163 | Dallas | Texas | 75246 | — |
| Local Institution - 0172 | Houston | Texas | 77030 | — |
| Local Institution - 0137 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05002569, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05002569 live on ClinicalTrials.gov.